Letairis (ambrisentan)

By Business Review Editor

Pharma Deals Review: Vol 2007 Issue 89 (Table of Contents)

Published: 7 Nov-2007

DOI: 10.3833/pdr.v2007.i89.259     ISSN: 1756-7874

Section: Deal Trackers



Letairis™ (ambrisentan) was recently approved in the US for the treatment of pulmonary arterial hypertension (PAH), a condition in which there is higher than normal blood pressure in the pulmonary artery, which can lead to heart and lung degradation, and eventually, death...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details